CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. The company describes itself as a full-service, non-clinical global drug-development partner. Its work spans research-model technologies, discovery and safety-assessment services (both GLP and non-GLP), and manufacturing-support products and services, covering client needs from target identification through non-clinical development and product release.

Revenue is organized around three reportable segments. In 2025, total revenue was $4.0 billion, with Research Models and Services contributing 21.1%, Discovery and Safety Assessment contributing 59.8%, and Manufacturing Solutions contributing 19.1%. The company runs more than 120 sites across more than 20 countries, and it acquired certain assets of K.F. (Cambodia) Ltd. in January 2026 to support non-human-primate supply operations for DSA and RMS third-party sales.

As a gauge of competitive moat, the financial returns are currently weak. Net margin is negative 6.0% and return on equity is negative 7.7%. A wide, durable moat would normally show consistently positive, above-cost margins and ROE, but those numbers are not present in this snapshot. The global footprint and integrated service portfolio are scale advantages, yet the recent negative profitability suggests pricing pressure, restructuring costs, or volume weakness in parts of the non-clinical research market.

Financial posture

Charles River Laboratories carries a market capitalization of $13.9 billion and trades at a P/E ratio of negative 59.6. The negative P/E reflects the company’s current unprofitability over the trailing period: net margin is negative 6.0% and ROE is negative 7.7%. When a stock shows a negative P/E, it simply means reported earnings are below zero, so the multiple cannot be interpreted as a valuation discount in the normal sense.

The stock’s beta is 1.41, meaning it has historically moved more than the broader market. As of the snapshot, the share price is $288.5, the RSI is 60.1, and the 50-day exponential moving average is $257.03. Price is above that moving average, which only describes recent momentum and does not imply any recommended action.

In plain terms, CRL is a mid-cap healthcare-services company with significant operating leverage and currently depressed bottom-line returns. Investors evaluating the name would want to focus on when margins turn positive again and how much of the current loss is tied to restructuring versus underlying demand.

Strategic priorities & outlook

According to the company’s most recent 10-K filing, Charles River’s near-term priorities center on streamlining operations and integrating its service portfolio. The company plans to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within DSA and RMS. It also intends to integrate Discovery Services and Safety Assessment into one overarching DSA organization, supported by a combined sales force and leadership structure.

Operationally, the company is targeting the objective of being the scientific partner of choice by delivering a comprehensive and integrated portfolio aimed at accelerating biomedical research and therapeutic innovation. It also continues to seek opportunities to expand Biologics Testing Solutions service offerings and facilities in the United States and Europe.

These priorities imply that cost rationalization and cross-selling are central to the next phase of the business. The site-count reduction could improve margins over time, but it also carries execution risk if capacity cuts come faster than demand growth.

Macro & geopolitical exposure

As a Medical – Diagnostics & Research business with global operations, Charles River is exposed to several macro and geopolitical factors. Industry-wide, non-clinical research services are heavily regulated. Studies must meet FDA, EMA, and other global GLP and animal-welfare standards, so any tightening of safety rules, environmental permitting, or animal-use restrictions can raise compliance costs or limit access to research models.

Trade policy matters because the company sources and ships biological models, specialized reagents, and testing materials across borders. Tariffs, export controls, or customs delays can increase costs and disrupt study timelines. Currency exposure is also real, given revenue generated across more than 20 countries; movements in the U.S. dollar versus the euro, pound, yen, and other currencies affect translated results.

Broader biotech funding cycles influence demand as well. When venture capital and pharmaceutical R&D budgets are strong, outsourcing to preclinical partners increases; when funding tightens, discovery and safety-assessment spending can slow. Supply-chain reliability for living research models and specialty consumables is another recurring industry sensitivity.

Recent developments

Recent news coverage has focused heavily on post-earnings performance and portfolio positioning. On September 4, 2026, Zacks noted that Charles River had risen 10.5% since its last earnings report in a piece titled “Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?” A few days earlier, on September 1, 2026, Zacks also published “Is This the Right Time to Add CRL Stock to Your Portfolio?” signaling renewed attention from the quantitative-research side.

On August 31, 2026, Defense World ran “Contrasting Charles River Laboratories International (NYSE:CRL) and IB Acquisition (NASDAQ:IBAC),” which compared the two companies. Separately, on August 27, 2026, Fool.com published “Wall Street Is Now Backing the Clarity Act. Here’s the Most Likely Scenario for What Happens Next With Crypto.” That headline is not directly related to Charles River’s operations, but it illustrates the kind of broad market narrative that can influence sentiment around healthcare names with above-average beta.

Earnings behavior & post-earnings drift

Charles River has beaten earnings expectations in each of the last eight reported quarters, for a 100% beat rate. The average earnings surprise across those eight quarters is 9.3%. Looking at the five trading days following each report, the average price move has been a positive 1.24%, classified as an “up” drift.

The most recent four quarters show how a beat does not always translate into a straightforward short-term rally. On August 5, 2026, CRL reported actual EPS of $3.02 against an estimate of $2.74, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five sessions. On May 7, 2026, the company reported actual EPS of $2.06 versus an estimate of $1.96, a 5.1% beat, yet the stock fell 2.23% the next day and dropped 12.42% over the following five sessions.

Earlier, on February 18, 2026, actual EPS of $2.39 beat the $2.33 estimate by 2.6%, producing a next-day gain of 3.95% and a five-day gain of 6.05%. On November 5, 2025, actual EPS of $2.43 beat the $2.32 estimate by 4.7%, with the stock rising 1.9% the next day and 2.27% over five days. The next scheduled earnings release is November 4, 2026, before the market open, with a consensus EPS estimate of $2.96.

If you want to go deeper, consider reviewing the full institutional verdict on CRL, including analyst estimate revisions, sector-level R&D spending trends, and the company’s own restructuring targets, before forming any opinion.